This article is more than 5 years old. Information may no longer be current.

Kyorin will market some Allergan glaucoma products in Japan

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

IRVINE, Calif. — Kyorin Pharmaceutical Co. will develop and market Allergan’s Alphagan glaucoma drugs in Japan, according to a press release from Allergan.

Under terms of the agreement, Kyorin will be responsible for developing and commercializing Alphagan (brimonidine tartrate 0.2%) and Alphagan P (brimonidine tartrate 0.15% preserved with Purite) in Japan and will incur associated costs. Kyorin will give Allergan an up-front payment as well as development and commercialization milestone payments, the press release said.

Allergan said the Japanese glaucoma market is estimated to be more $500 million annually. The Alphagan franchise is the third largest-selling glaucoma franchise in the world, with 2003 global sales of $287 million, the press release said.